BRIM BiotechnologyTPE:6885 -0.46%40 Days Payable is 25.60 as of Dec. 2025, which is 65% below its 10-year median of 73.26. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 700 Biotechnology companies, BRIM Biotechnology ranks worse than 61.86% on this metric.
The historical rank and industry rank for BRIM Biotechnology's Days Payable or its related term are showing as below:
TPE:6885'
s Days Payable Range Over the Past 10 Years
Min: 64.48 Med: 73.26 Max: 73.26
Current: 64.48
During the past 7 years, BRIM Biotechnology's highest Days Payable was 73.26. The lowest was 64.48. And the median was 73.26.
TPE:6885's Days Payable is ranked worse than 61.86% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs TPE:6885: 64.48
BRIM Biotechnology's Days Payable
increased
from Dec. 2024 (0.00) to Dec. 2025 (25.60).
It may suggest that BRIM Biotechnologydelayed paying its suppliers.
BRIM Biotechnology Days Payable Related Terms
BRIM Biotechnology Days Payable Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6885 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, BRIM Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRIM Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BRIM Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where BRIM Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BRIM Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIM Biotechnology (TPE:6885) has a Days Payable of 25.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BRIM Biotechnology and its competitors. This is 65% below median its historical median of 73.26. Over the past decade, BRIM Biotechnology's Days Payable has ranged from 64.48 to 73.26. According to the industry distribution chart, BRIM Biotechnology ranks #433 out of 700 companies in the Biotechnology industry, placing it in the top 61.9%.
Is BRIM Biotechnology's Days Payable too high?
BRIM Biotechnology's current Days Payable of 25.60 is 65% below median its 10-year median of 73.26. Over the past 10 years, this metric has ranged from a low of 64.48 to a high of 73.26. The Biotechnology industry median Days Payable is 113.10. BRIM Biotechnology's value of 25.60 is 77.4% below this industry median. Based on the distribution chart, BRIM Biotechnology ranks #433 out of 700 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BRIM Biotechnology ranks #433 out of 700 companies for Days Payable. This places BRIM Biotechnology in the lower half of its industry. The industry median Days Payable is 113.10. BRIM Biotechnology's value of 25.60 is 77.4% below this benchmark. Historically, BRIM Biotechnology's own Days Payable has ranged from 64.48 to 73.26 over the past decade. While the company's 10-year median is 73.26 vs. the industry median of 113.10, BRIM Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRIM Biotechnology's current Days Payable of 25.60 is 77.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BRIM Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRIM Biotechnology's current Days Payable is 25.60, which is 65% below median its own 10-year median of 73.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current Days Payable is 25.60, which is 65% below median its 10-year median of 73.26 and 77.4% below the Biotechnology industry median of 113.10. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Days Payable is 25.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
Days Payable: 25.60 (65% below median its 10-year median of 73.26)
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
Industry Position: 77.4% below the Biotechnology median (#433 of 700)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
